Published in Telemedicine Week, December 5th, 2006
In this study, AMG 706 showed encouraging clinical activity in patients with advanced high-dose imatinib-resistant gastrointestinal stromal tumors (GIST). These data were presented in an oral session at the Connective Tissue Oncology Society (CTOS) meeting in Venice, Italy.
"AMG 706 targets tyrosine kinases, a family of proteins thought to play an important role in controlling cell development and tumor growth," said Robert Benjamin, MD, chair, Sarcoma Medical Oncology professor, M.D. Anderson Cancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Week